Pharmacokinetics, pharmacodynamics and safety of tenofovir alafenamide in HIV-1 infected patients.

Trial Profile

Pharmacokinetics, pharmacodynamics and safety of tenofovir alafenamide in HIV-1 infected patients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2014

At a glance

  • Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 09 Apr 2014 New trial record
    • 06 Feb 2014 Results published in the Journal of Antimicrobial Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top